Enkay Therapeutics Submits Clinical Application for NK042 Cell Injection in China Following FDA Clearance of NK010 in the U.S.

On February 28, 2024, the official website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) showed that the "NK042 Cell Injection" submitted by Shanghai Enke Cell Technology Co., Ltd. (Enke Pharmaceuticals) has been accepted.

According to the inquiry, NK042 is the first clinical product pipeline of Enka Therapeutics declared in China. NK042 is an engineered modification expressing multiple activating receptors (NKR).NK Cell Therapy: Specific and detailed information has not been disclosed.

Enkaicell, founded in 2020, is a biotechnology company focused on developing NK cell therapeutic drugs, with ten R&D pipelines currently listed on its official website.

EnCaymanMedicineThe founder, Tian Zhigang, is a leading figure in the field of immunology in China and an academician of both the Chinese Academy of Engineering and the European Academy of Sciences. Academician Tian Zhigang and his team have over thirty years of accumulated research and application development experience in NK cell biology.

In fact, Enkaice Pharmaceutical's most advanced pipeline is NK010, which received FDA IND approval in the United States on January 17, 2024. NK010 is an allogeneic peripheral blood NK cell drug without genetic modification, developed for the treatment of solid tumors such as ovarian cancer and liver cancer.

Disclaimer: The content is sourced from Enka Therapeutics, BioValley, and other sources. The content of this article aims to share knowledge., all content is for reference only and does not constitute any advice.